Potency of Veterinary Rabies Vaccines Marketed in Sri Lanka
Open Access
Abstract
Seven brands of veterinary rabies vaccines are commercially available in Sri Lanka, but there is no established procedure to test the potency of the vaccines at the local level, especially prior to their release. The aim of this study was to test the potency of these vaccines using a mouse challenge test in collaboration with the EU/WOAH/WHO Reference Laboratory for Rabies, ANSES-Nancy, France. Based on the European Pharmacopoeia, the inactivated rabies vaccines complied with the mouse potency test if the estimated potency is ≥1.0 IU in the smallest prescribed dose. Among the eight tested vaccines, four single-dose preparations (Rabisin™, Raksharab™, Nobivac™ RL, and Nobivac™ Rabies) were compliant, with potencies of 12 IU/dose, 7.2 IU/dose, 4.4 IU/dose, and 3.4 IU/dose, respectively. Three of the single-dose preparations (Canvac™ R, Defensor™ 3, and Rabies killed vaccine) were not compliant, with potency values <1.0 IU/dose. One multidose preparation (Raksharab™ multidose) had a potency of 1.3 IU/dose, even though the test was not validated. Based on these results, it appears that some rabies vaccine batches that are currently available in the local market do not comply with the mouse potency test. Testing the vaccines’ potency before registration and release to the market appears to be an important step to allow good immunization to animals during pre-exposure vaccination programs.Keywords
Funding Information
- Boehringer Ingelheim France (4111206, CS 40009–54220)
- ANSES-Nancy (4111206, CS 40009–54220)
This publication has 13 references indexed in Scilit:
- Mission Indradhanush and the counterfeit drug trade in IndiaThe Lancet Infectious Diseases, 2015
- A Step Forward in the Quality Control Testing of Inactivated Rabies Vaccines — Extensive Evaluation of European Vaccines by Using Alternative Methods to the In Vivo Potency TestsAlternatives to Laboratory Animals, 2015
- EDQM biological reference preparation for rabies vaccine (inactivated) for veterinary use.2015
- The health and economic effects of counterfeit drugs.2014
- Collaborative study for validation of a serological potency assay for rabies vaccine (inactivated) for veterinary use.2010
- Inferior rabies vaccine quality and low immunization coverage in dogs (Canis familiaris) in ChinaEpidemiology and Infection, 2008
- Canine vaccination—Providing broader benefits for disease controlVeterinary Microbiology, 2006
- Rabies in North America and EuropeJournal of the Royal Society of Medicine, 2002
- Rabies in North America and EuropeJournal of the Royal Society of Medicine, 2002
- Laboratory techniques in rabies: the NIH test for potency.1973